Dianthus Therapeutics reported Q3 2025 earnings on November 5, 2025, with a net loss of $36.8 million or $0.97 per share, compared to $25.2 million or $0.74 per share in Q3 20242
Q3 2025 revenue was $0.396 million, significantly down from $2.17 million a year ago1
The company holds an estimated $525 million in adjusted cash, cash equivalents and investments as of September 30, 2025, projected to provide runway into 20282
R&D expenses for Q3 2025 were $32.5 million, up from $25.5 million a year ago, driven by higher clinical costs and increased headcount to support claseprubart Phase 2 and Phase 3 development2
For the nine-month period ended September 30, 2025, the company reported revenue of $1.75 million compared to $4.91 million a year ago, with a net loss of $97.91 million versus $56.53 million a year ago1
The earnings missed analyst consensus estimates, with EPS of -$0.97 versus Zacks Consensus Estimate of -$0.863
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases2
Sources:
1. https://www.marketscreener.com/news/dianthus-therapeutics-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-sep-ce7d5cddde8efe21
2. https://www.globenewswire.com/news-release/2025/11/05/3181899/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q3-Financial-Results.html
3. https://finviz.com/news/219930/dianthus-therapeutics-inc-dnth-reports-q3-loss-lags-revenue-estimates